❌ HB263
Cap cost sharing for prescription insulin drugs, diabetes devices
Current Status: In House Committee (Health)
Summary
The bill caps cost sharing for prescription insulin drugs and diabetes devices at $35 and $100 respectively for a thirty-day supply, applicable to health plans issued or renewed after the effective date. It prohibits health plan issuers from requiring cost sharing above these amounts, regardless of other cost-sharing requirements. The bill allows health plan issuers to reduce cost-sharing amounts below these caps.
Rationale
The bill introduces government-mandated cost-sharing limits, which conflicts with the Libertarian principles of minimal government intervention in personal and economic matters. Both the LP and LPO platforms emphasize free markets and individual choice, suggesting that such mandates may undermine these principles.
Risks and Concerns
- Increased government control over healthcare pricing
- Potential for reduced competition among healthcare providers
- Risk of unintended consequences in the healthcare market